Our Firm is representing numerous Risperdal lawsuit plaintiffs who have put forth allegations similar to those included in this complaint. We are monitoring the litigation surrounding this medication very closely.
New York, New York (PRWEB) September 23, 2014
Risperdal lawsuits (http://www.drugbot.com/risperdal/lawsuit/) continue to move forward in courts around the country, Bernstein Liebhard LLP reports. According to an Order issued in U.S. District Court, Middle District of Florida on September 19th, the Court has dismissed fraud and negligence per se claims from a case filed in that jurisdiction on behalf of a man who allegedly developed gynecomastia (male breast growth) and other complications due to his use of Risperdal. In dismissing the Plaintiff’s negligence per se claim, U.S. District Judge John E. Steele noted that Florida law does not recognize causes of action based on violations of the Food, Drug and Cosmetic Act. Judge Steele also dismissed fraud claims accusing the manufacturers of Risperdal of failing to adequately disclose the drug’s risk after finding that they were not adequately pled.(Gallant v. Ortho-McNeil-Jannsen Pharmaceuticals Inc., et al., No. 2:14-263)
“Our Firm is representing numerous Risperdal lawsuit plaintiffs who have put forth allegations similar to those included in this complaint. We are monitoring the litigation surrounding this medication very closely,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Litigation
Court documents indicate that Risperdal is the subject of hundreds of product liability claims that allege the atypical antipsychotic medication caused patients to develop serious complications, including gynecomastia. The majority of these cases have been filed in a mass tort litigation now underway in the Philadelphia Court of Common Pleas in Pennsylvania, where Bernstein Liebhard LLP is actively filing claims. Among other things, Risperdal lawsuits accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing its potential risks, and of improperly marketing the drug for unapproved, off-label uses. (Risperdal Litigation, case number 100300296)
Nearly one year ago, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle allegations brought against them by the U.S. Department of Justice over the marketing of Risperdal and other medications. Among other things, the government had charged the companies with improperly marketing Risperdal for use in children before pediatric indications were approved in 2006, and further alleged that they had concealed the serious side effects linked to its use. In announcing the accord last November, the Justice Department said it represented one of the largest federal healthcare fraud settlements in U.S. history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal-related gynecomastia may be entitled to compensation for their injury-related damages.Find out more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.drugbot.com/
https://plus.google.com/115936073311125306742?rel=author